{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:13:10Z","timestamp":1791418390198,"version":"4.3.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013885","name":"Kementerian Kesihatan Malaysia","doi-asserted-by":"publisher","award":["NMRR-21-822-59745"],"award-info":[{"award-number":["NMRR-21-822-59745"]}],"id":[{"id":"10.13039\/501100013885","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.05.075","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T09:17:53Z","timestamp":1654247873000},"page":"4394-4402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study"],"prefix":"10.1016","volume":"40","author":[{"given":"Norazida","family":"Ab Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Tsuey","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei Yee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sing Chet","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azuana","family":"Ramli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Nurhafizah","family":"Saharudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teck Long","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelyne Bani","family":"Anak Jam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Aliya","family":"Ayub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Sevalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashidah","family":"Bahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Nadziroh","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatihah","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheamini","family":"Sivasampu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalaiarasu M","family":"Peariasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.075_b0005","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus (COVID-19) Vaccinations Published online at OurWorldInData.org; 2020 [Available from: https:\/\/ourworldindata.org\/covid-vaccinations."},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.075_b0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41577-020-0372-8","article-title":"Optimizing safety surveillance for COVID-19 vaccines","volume":"20","author":"Chandler","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"S2","key":"10.1016\/j.vaccine.2022.05.075_b0015","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.2105\/AJPH.2008.143081","article-title":"What should an ideal vaccine postlicensure safety system be?","volume":"99","author":"Griffin","year":"2009","journal-title":"Am J Public Health"},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.075_b0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.vaccine.2018.02.012","article-title":"Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000\u20132015","volume":"36","author":"Lei","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.075_b0025","unstructured":"COVID-19 vaccines: safety surveillance manual, second edition. Geneva: World Health Organization; 2021."},{"issue":"7881","key":"10.1016\/j.vaccine.2022.05.075_b0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China's COVID vaccines have been crucial - now immunity is waning","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.05.075_b0035","unstructured":"COVID-19 Immunisation Task Force Malaysia (CITF-Malaysia) Ministry of Health Malaysia. Open data on Malaysia's National COVID-19 Immunisation Programme. 2021 [Available from: https:\/\/github.com\/citf-malaysia\/citf-public."},{"key":"10.1016\/j.vaccine.2022.05.075_b0040","unstructured":"Malaysian Pharmacovigilance Guidelines (Second Edition). Selangor, Malaysia: National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia; 2016."},{"key":"10.1016\/j.vaccine.2022.05.075_b0045","unstructured":"Malaysian Health Data Warehouse (MyHDW) - 2015-2016 Start up: initiation. Malaysia: Health Informatics Centre, Planning Division, Ministry of Health Malaysia; 2017."},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.075_b0050","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S0950268811001531","article-title":"Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice","volume":"139","author":"Weldeselassie","year":"2011","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.075_b0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.05.075_b0060","series-title":"medRxiv : the preprint server for health sciences","article-title":"The Physiologic Response to COVID-19 Vaccination","author":"Quer","year":"2021"},{"key":"10.1016\/j.vaccine.2022.05.075_b0065","doi-asserted-by":"crossref","first-page":"102489","DOI":"10.1016\/j.janxdis.2021.102489","article-title":"Immunization stress-related responses: Implications for vaccination hesitancy and vaccination processes during the COVID-19 pandemic","volume":"84","author":"Taylor","year":"2021","journal-title":"J Anxiety Disord"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.075_b0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40119-021-00248-0","article-title":"Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview","volume":"11","author":"Shiravi","year":"2022","journal-title":"Cardiol. Therapy"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.075_b0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s43678-021-00250-4","article-title":"Atrial fibrillation as a precursor of mRNA-1273 SARS-CoV-2 vaccine-induced pericarditis","volume":"24","author":"Scheuermeyer","year":"2022","journal-title":"Can J Emerg Med"},{"key":"10.1016\/j.vaccine.2022.05.075_b0080","doi-asserted-by":"crossref","unstructured":"Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ (Clinical research ed). 2021;374:n1931.","DOI":"10.1136\/bmj.n1931"},{"issue":"14","key":"10.1016\/j.vaccine.2022.05.075_b0085","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.vaccine.2022.05.075_b0090","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.075_b0095","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jcmm.17137","article-title":"Cardiovascular and haematological events post COVID-19 vaccination: A systematic review","volume":"26","author":"Al\u2010Ali","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.075_b0100","article-title":"Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England","volume":"6","author":"Higgins","year":"2022","journal-title":"Res Pract Thrombosis Haemostasis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.075_b0105","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.075_b0110","doi-asserted-by":"crossref","first-page":"e1003926","DOI":"10.1371\/journal.pmed.1003926","article-title":"Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England","volume":"19","author":"Whiteley","year":"2022","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.075_b0115","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.vaccine.2022.05.075_b0120","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 Vaccination in a Large Health Care Organization","volume":"385","author":"Witberg","year":"2021","journal-title":"New Engl. J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.075_b0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis With COVID-19 mRNA Vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2022.05.075_b0130","unstructured":"Centers for Disease Control and Prevention National Center for Immunization & Respiratory Diseases. COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP) [Webinar] Atlanta, GA: Centers for Disease Control and Prevention; 2021 [presented 23 Jun 2021; cited 20 Dec 2021]. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/03-COVIDShimabukuro-508.pdf."},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.075_b0135","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.075_b0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","article-title":"Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study","volume":"22","author":"Wan","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.075_b0145","doi-asserted-by":"crossref","unstructured":"Li X, Ravent\u00f3s B, Roel E, Pistillo A, Martinez-Hernandez E, Delmestri A, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ (Clinical research ed). 2022;376:e068373.","DOI":"10.1136\/bmj-2021-068373"},{"key":"10.1016\/j.vaccine.2022.05.075_b0150","unstructured":"Ministry of Health Malaysia. Health Facts 2019. 2019."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.075_b0155","doi-asserted-by":"crossref","DOI":"10.5334\/gh.791","article-title":"Trends of Stroke Incidence and 28-Day All-Cause Mortality after a Stroke in Malaysia: A Linkage of National Data Sources","volume":"16","author":"Hwong","year":"2021","journal-title":"Global Heart"},{"issue":"10292","key":"10.1016\/j.vaccine.2022.05.075_b0160","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/S0140-6736(21)01106-5","article-title":"Divergent vaccination policies could fuel mistrust and hesitancy","volume":"397","author":"Forman","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2022.05.075_b0165","unstructured":"Ministry of Health Malaysia. Clinical guidelines on COVID-19 vaccination in Malaysia (4th Edition). Malaysia; 2021."},{"key":"10.1016\/j.vaccine.2022.05.075_b0170","doi-asserted-by":"crossref","unstructured":"Husby A, Hansen JV, Fosb\u00f8l E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ (Clinical research ed). 2021;375:e068665.","DOI":"10.1136\/bmj-2021-068665"},{"issue":"38","key":"10.1016\/j.vaccine.2022.05.075_b0175","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.08.085","article-title":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines","volume":"37","author":"Kochhar","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.075_b0180","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/vaccines9121381","article-title":"PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio","volume":"9","author":"Suah","year":"2021","journal-title":"Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:18:04Z","timestamp":1759403884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22007009"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}